Related Experiment Video
Updated: Sep 7, 2025
Assessment of Plasma Coagulation on Liver Tissue in a Large Animal Model In Vivo
Published on: August 4, 2018
Severe coagulopathy caused by cefminox sodium in a liver cirrhosis patient: a case report
Shuling Wu1, Xiaoyue Bi1, Yanjie Lin2
1Department of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University, No. 8 Jingshun East Street, Chaoyang District, Beijing, 100015, China.
Abstract:
Cefminox sodium is an antimicrobial agent with broad-spectrum antibacterial activity against Gram-positive and Gram-negative bacteria. Cefminox sodium has high security in clinical practice for its few adverse effects such as coagulation dysfunction, which is rare in clinical treatment. Even in patients suffering from chronic liver disease with coagulation dysfunction, it rarely leads to further deterioration of coagulation function. Therefore, patients with chronic liver disease develop severe coagulation dysfunction during the application of cefminox sodium, which is often mistaken for worsening of liver disease other than considered to be the side effect of the drug. Therefore, we report a 55-year-old female patient with liver cirrhosis and hepatocellular carcinoma treated with cefminox sodium intravenously twice for peritonitis. During the treatments, severe coagulopathy occurred, and the coagulation function quickly recovered after drug withdrawal. The diagnosis and treatment of this patient provides us with ideas for dealing with similar problems in clinical practice in the future.
Insights
Cefminox sodium, an antibiotic, can rarely cause severe bleeding issues (coagulopathy) in patients with liver disease. This adverse effect may be mistaken for worsening liver function, highlighting the need for careful monitoring.
Area of Science:
- Pharmacology
- Hepatology
- Infectious Diseases
Background:
- Cefminox sodium is a broad-spectrum antibiotic with a generally favorable safety profile.
- Coagulation dysfunction is a rare adverse effect of cefminox sodium, even in patients with pre-existing liver conditions.
- Differentiating drug-induced coagulopathy from liver disease progression is clinically challenging.
Purpose of the Study:
- To report a case of severe coagulopathy induced by cefminox sodium in a patient with liver cirrhosis and hepatocellular carcinoma.
- To highlight the potential for cefminox sodium to cause significant bleeding complications in patients with compromised liver function.
- To emphasize the importance of considering drug side effects in patients with chronic liver disease presenting with coagulation abnormalities.
Main Methods:
- Case report of a 55-year-old female patient with liver cirrhosis and hepatocellular carcinoma.
- Intravenous administration of cefminox sodium for peritonitis.
- Monitoring of coagulation function during and after antibiotic treatment.
Main Results:
- The patient developed severe coagulopathy during cefminox sodium treatment.
- Coagulation function rapidly improved upon discontinuation of the drug.
- The adverse event was initially misattributed to the progression of liver disease.
Conclusions:
- Cefminox sodium can induce severe coagulopathy, which may be misdiagnosed as worsening liver disease in patients with chronic liver conditions.
- Clinicians should consider cefminox sodium as a potential cause of coagulopathy in patients with liver cirrhosis and hepatocellular carcinoma.
- Prompt recognition and drug withdrawal are crucial for managing this rare but serious adverse effect.
Related Concept Videos
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
01:28Esophageal Varices-II: Clinical Features and Management
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
01:28Pleural Effusion II: Symptoms and Management
A pleural effusion is the abnormal collection of fluid between the parietal and visceral pleura layers of tissue that form the lining of the lungs and chest cavity. It can occur independently or due to surrounding parenchymal diseases, such as infection, malignancy, or inflammatory conditions.
Clinical Manifestations:
01:29Venous Thrombosis III: Interprofessional Care
01:27Inflammatory Bowel Disease I: Ulcerative Colitis
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...